Polycyclo Ring System Patents (Class 514/766)
  • Patent number: 5720975
    Abstract: The invention relates to the use of incense (olibanum), incense extracts, substances contained in incense, their physiologically acceptable salts, their derivatives and their physiological salts, pure boswellic acid, of a physiologically acceptable salts, of a derivative, of a salt of the derivative, for production of a medicament for the prevention or treatment of Alzheimer's disease.
    Type: Grant
    Filed: February 5, 1997
    Date of Patent: February 24, 1998
    Inventor: Rainer Etzel
  • Patent number: 5709890
    Abstract: An insecticide composition is enhanced from the standpoint of its ability to be absorbed by insects, such as red fire ants, particularly dithiophosphate ester pesticides by the addition of a small amount of a water soluble non-aromatic polyorganic acid or salt form thereof such as polyaspartic acid, particularly preferred with a molecular weight in the range of about 3000 to 40,000.
    Type: Grant
    Filed: March 20, 1997
    Date of Patent: January 20, 1998
    Assignee: Donlar Corporation
    Inventor: J. Larry Sanders
  • Patent number: 5677343
    Abstract: This invention pertains to the discovery that condensation polymers of an aldehyde and aromatic sulfonic acids and fractions thereof, such as formaldehyde naphthalene-sulfonic acid condensation polymers, can abrogate HIV gp120 binding to CD4, as demonstrated in CD4/gp120 binding assays. In addition to gp120 binding inhibition, the compounds have been shown to inhibit HIV-induced syncytia formation and infectivity of CD+ cells. The use of this compound has been shown to be non-cytotoxic and non-inhibitory to antigen induced T lymphocyte proliferation. Based on these findings, these compounds can be used as a therapeutic agent for the treatment of acquired immunodeficiency syndrome (AIDS), as well as AIDS-related complex (ARC), AIDS-related dementia and non-symptomatic HIV infection. The compounds can also be used to treat blood preparations.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: October 14, 1997
    Assignee: Procept, Inc.
    Inventors: Shyam K. Singh, Raymond J. Patch, Peter V. Pallai, Edith A. Neidhardt, Gerard P. Palace, Kevin J. Willis, Theresa M. Sampo, Kevin W. McDonald, Zhan Shi
  • Patent number: 5653991
    Abstract: Closely related formulations of GRAS food additives serve as insect repellents, insecticides and larvicides. The ingredients of the repellent, insecticide and larvicide also exhibit useful disinfectant properties against vector-borne pathogenic microorganisms.
    Type: Grant
    Filed: May 9, 1995
    Date of Patent: August 5, 1997
    Assignee: The Rod Family Trust
    Inventor: Robert L. Rod
  • Patent number: 5629351
    Abstract: Disclosed herein is a novel fraction comprising a mixture of boswellic acids, wherein the fraction exhibits anti-inflammatory and antiulcerogenic activities. Also disclosed is a novel boswellic acid compound exhibiting anti-inflammatory, antiathritic and antiulcerogenic activities. Also disclosed is a process for isolating a boswellic acid fraction and individual boswellic acids therefrom.
    Type: Grant
    Filed: April 13, 1995
    Date of Patent: May 13, 1997
    Assignee: Council of Scientific & Industrial Research
    Inventors: Subhash C. Taneja, Vijay K. Sethi, Kanaya L. Dhar, Randhir S. Kapil
  • Patent number: 5614559
    Abstract: This invention pertains to the discovery that condensation polymers of an aldehyde and aromatic sulfonic acids and fractions thereof, such as formaldehyde naphthalene-sulfonic acid condensation polymers, can abrogate HIV gp120 binding to CD4, as demonstrated in CD4/gp120 binding assays. In addition to gp120 binding inhibition, the compounds have been shown to inhibit HIV-induced syncytia formation and infectivity of CD+ cells. The use of this compound has been shown to be non-cytotoxic and non-inhibitory to antigen induced T lymphocyte proliferation. Based on these findings, these compounds can be used as a therapeutic agent for the treatment of acquired immunodeficiency syndrome (AIDS), as well as AIDS-related complex (ARC), AIDS-related dementia and non-symptomatic HIV infection. The compounds can also be used to treat blood preparations.
    Type: Grant
    Filed: May 19, 1994
    Date of Patent: March 25, 1997
    Assignee: Procept Inc.
    Inventors: Shyam K. Singh, Raymond J. Patch, Peter V. Pallai, Edith A. Neidhardt, Gerard P. Palace, Kevin J. Willis, Theresa M. Sampo, Kevin W. McDonald, Zhan Shi
  • Patent number: 5550145
    Abstract: An antimicrobial composition comprising an antimicrobially effective amount of a combination of: A) a monoglyceride of lauric acid, a monoglyceride of monomyristic acid or a mixture of these monoglycerides, and B) at least one chemical substance selected from the following groups: i) local anesthetics of the amide type; ii) carbamide, iii) antibacterial substances in the form of steroid antibiotics, imidazole derivatives or nitroimidazole derivatives, and iv) diols with 3-6 carbon atoms, and C) optionally, a conventional physiologically acceptable carrier and/or physiologically acceptable additives. A process for the preparation of this composition by heating (A) to the transition temperature of the lipid, adding (B), and optionally (C), and cooling the mixture to form a solid lipid crystal composition. Use of the composition for the preparation of a dermatological preparation for combatting bacteria and fungi or as a preservative additive in a cosmetic product, a food product, or a medical product.
    Type: Grant
    Filed: September 27, 1994
    Date of Patent: August 27, 1996
    Assignee: Bioglan AB
    Inventors: Karin Olund, Lena-Karin L utz, Rickard Bryland, .ANG.ke Lindahl
  • Patent number: 5538983
    Abstract: Various first messengers linked to phospholipase C, including acetylcholine and interleukin-1, regulate the production both of the secreted form of the amyloid protein precursor and of amyloid .beta.-protein. Intracellular signals which are responsible for mediating these effects have now been identified, and that activation of phospholipase C may affect APP processing by either of two pathways, one involving an increase in protein kinase C and the other an increase in cytoplasmic calcium levels. The effects of calcium on APP processing appear to be independent of protein kinase C activation. The observed effects of calcium on APP processing are of therapeutic utility in the treatment of Alzheimer-type amyloidosis.
    Type: Grant
    Filed: April 29, 1994
    Date of Patent: July 23, 1996
    Assignee: The Rockefeller University
    Inventors: Joseph D. Buxbaum, Paul Greengard
  • Patent number: 5455280
    Abstract: According to the present invention, there is provided a method for treating chronic lymphocytic leukemia (CLL) in a mammal. Beta-carotene is administered to the mammal in CLL therapeutically effective amounts. The invention also contemplates a method for treating T-cell chronic lymphocytic leukemia (T-CLL). T-CLL therapeutically effective amounts of beta-carotene are administered. In further embodiment, a method for lowering or maintaining the level of white blood cells in a mammal having chronic lymphocytic leukemia is provided. White blood cell therapeutically effective amounts of beta-carotene are administered to the mammal.
    Type: Grant
    Filed: December 13, 1993
    Date of Patent: October 3, 1995
    Inventor: Steven Baranowitz
  • Patent number: 5434122
    Abstract: An herbal treatment for plant growth comprising a water solution of extracts of the type withdrawn at elevated temperature from Artemesia plants and the like, applicable to the root structure of plants and as an external spray.
    Type: Grant
    Filed: August 13, 1993
    Date of Patent: July 18, 1995
    Assignee: Allor Foundation
    Inventors: Marianne Lorina, Robert H. Rines, Carol M. Rines, Justice C. Rines
  • Patent number: 5411993
    Abstract: Aqueous solution preparations which comprise azulene sodium sulfonate as an active ingredient and 20 w/v % or more of a polyhydric alcohol are disclosed wherein azulene sodium sulfonate is stable in the preparation for a prolonged period of time is suited for use in treating inflammation of the oral cavity and/or throat.
    Type: Grant
    Filed: July 12, 1993
    Date of Patent: May 2, 1995
    Assignees: Nihon Tenganyaku Kenkyusho Co, Ltd., Meiji Milk Prod. Co., Ltd.
    Inventors: Tokihiko Yamamoto, Tomoyuki Yamaoka, Yoshiaki Yoshida, Kazuo Shin, Hiromitu Aonuma, Tutomu Tanaka
  • Patent number: 5399587
    Abstract: The present invention relates to novel potassium channel agonists which are useful in activating the calcium activated Maxi-K potassium channel in mammalian neuronal and smooth muscle tissue. The claimed compounds are of the general formula: ##STR1## In addition, a novel microbiological process for producing the claimed compounds is described.
    Type: Grant
    Filed: December 13, 1993
    Date of Patent: March 21, 1995
    Assignee: Merck & Co., Inc.
    Inventors: Maria L. Garcia, Robert A. Giacobbe, Otto D. Hensens, Gregory J. Kaczorowski, Seok H. Lee, Owen B. McManus, Deborah L. Zink
  • Patent number: 5385915
    Abstract: A method of regulating phosphorylation of proteins involved in controlling processing or function of key proteins found in intracellular neurofibrillary tangles and extracellular amyloid plaques associated with Alzheimer disease comprising introducing an effective amount of a kinase modulator or phosphatase modulator, the modulator capable of increasing or decreasing the rate of proteolytic processing, or modulating the function, of said key proteins.
    Type: Grant
    Filed: June 7, 1993
    Date of Patent: January 31, 1995
    Assignee: The Rockefeller University
    Inventors: Joseph D. Buxbaum, Samuel E. Gandy, Paul Greengard
  • Patent number: 5348963
    Abstract: Agents which modulate or affect the intracellular trafficking and processing of proteins in the mammalian cell can be utilized to affect the trafficking and processing of APP, thereby inhibiting production of Alzheimer type amyloidosis. Particularly useful agents are chloroquine and its related derivatives such as primaquine.
    Type: Grant
    Filed: May 26, 1993
    Date of Patent: September 20, 1994
    Assignee: The Rockefeller University
    Inventors: Samuel E. Gandy, Gregg L. Caporaso, Paul Greengard
  • Patent number: 5338758
    Abstract: Four bicyclic terpenes isolated from a culture broth of Phoma sp SCF0592, ATCC 74077, pharmaceutical compositions containing them and their use as PAF antagonists to treat allergic and inflammatory diseases are disclosed.
    Type: Grant
    Filed: September 30, 1992
    Date of Patent: August 16, 1994
    Assignee: Schering Corporation
    Inventors: Min Chu, Mahesh Patel, Ann C. Horan, Vincent P. Gullo
  • Patent number: 5314693
    Abstract: Disclosed are (1) pest control chemicals against the pine wood nematodes containing an extract from a pine tree with an organic solvent, (2) a repellent against the pine wood nematodes containing .alpha.-humulene or a mixture of .alpha.-humulene and .beta.-bisabolene, (3) a repellent against the pine wood nematodes containing a mixture of .alpha.-pinene and calarene, (4) a nematicide against the pine wood nematodes containing methyl ferulate, (+)-pinoresinol or a mixture thereof, and (5) highly effective pest control chemicals against pine wood nematodes containing hydroxystilbenes or salts thereof which are prepared by synthesizing methoxystilbenes from benzyl phosphonates and methoxybenzaldehydes by a Wittig-Horner reaction, performing demethylation to obtain the hydroxystilbenes, and preparing the salts thereof by conventional methods if necessary.
    Type: Grant
    Filed: February 3, 1993
    Date of Patent: May 24, 1994
    Assignee: Kioritz Corporation
    Inventor: Takayuki Suga
  • Patent number: 5242932
    Abstract: Agents which modulate or affect the intracellular trafficking and processing of proteins in the mammalian cell can be utilized to affect the trafficking and processing of APP, thereby inhibiting production of Alzheimer type amyloidosis. Particularly useful agents are chloroquine and its related derivatives such as primaquine.
    Type: Grant
    Filed: December 17, 1991
    Date of Patent: September 7, 1993
    Assignee: The Rockefeller University
    Inventors: Samuel E. Gandy, Gregg L. Caporaso, Paul Greengard
  • Patent number: 5200429
    Abstract: An acne vulgaris treating and preventing topica, which comprises, as an active ingredient, at least one compound selected from the group consisting of caryophyllene, cedrene, longifolene and thujopsene. The topica exhibits sufficient inhibitory activity on proliferation of Propionibacterium acnes, a pathogenic bacterium causing acne vulgaris, at a small therapeutic dose without causing skin irritation.
    Type: Grant
    Filed: September 26, 1991
    Date of Patent: April 6, 1993
    Assignee: Takasago International Corporation
    Inventors: Toshiya Sato, Satoko Tsukada, Hamako Hata, Kenya Ishida
  • Patent number: 5104900
    Abstract: A new use for naphthalene comprising a snake repellant in the form of granules comprising 8% naphthalene, 32% sulfur and 60% montmorillonite. The compound is spread in a strip across an area where snakes are to be repelled and is effective against venomous and non-venomous varieties.
    Type: Grant
    Filed: February 28, 1990
    Date of Patent: April 14, 1992
    Inventor: James B. Tennyson
  • Patent number: 5063059
    Abstract: Microencapsulated pyrethroidal cockroach-controlling composition is provided, which has an excellent residual effect. The composition comprises phenylxylylethane and a pyrethroidal compound and is encapsulated in microcapsules formed of a polyurethane wall which have an average particle diameter of not more than 80 .mu.m, a wall thickness of not more than 0.3 .mu.m, and a value of the average particle diameter/wall thickness of 100-400.
    Type: Grant
    Filed: November 15, 1990
    Date of Patent: November 5, 1991
    Assignee: Sumitomo Chemical Co., Ltd.
    Inventors: Toshiro Ohtsubo, Shigenori Tsuda, Hitoshi Kawada, Goro Shinjo, Kozo Tsuji
  • Patent number: 5059591
    Abstract: Preparations of drugs in admixture with certain ligands are described which, when administered to animals or humans, are less toxic than conventional drug preparations. Although the toxicity of the drug-ligand preparations described is greatly reduced, the drug retains pharmacological activity.
    Type: Grant
    Filed: September 12, 1989
    Date of Patent: October 22, 1991
    Assignee: The Liposome Company, Inc.
    Inventors: Andrew S. Janoff, Mircea C. Popescu, Carl R. Alving, Michael W. Fountain, Robert P. Lenk, Marc J. Ostro, Paul A. Tremblay, Alan L. Weiner
  • Patent number: 5008295
    Abstract: A method of inhibiting the growth of cancers susceptible to treatment with .alpha.-carotene, which comprises: administering an effective cancer cell growth inhibiting amount of .alpha.-carotene to a manmal having said cancer cells.
    Type: Grant
    Filed: July 28, 1988
    Date of Patent: April 16, 1991
    Assignee: Lion Corporation
    Inventors: Hoyoku Nishino, Ryozo Iwasaki, Akio Okabe, Yuki Yogo
  • Patent number: 4985248
    Abstract: The new pharmaceutical composition and processes are provided for treating and preventing diabetes.The pharmaceutical composition is composed of three ingredients: Oleanolic acid, Saponins of Litchi and Kuguasu.The pharmaceutical composition is nontoxic.
    Type: Grant
    Filed: August 16, 1989
    Date of Patent: January 15, 1991
    Inventor: Yaguang Liu
  • Patent number: 4885314
    Abstract: Novel 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors which are useful as antihypercholesterolemic agents and are represented by the following general structural formulae (I) or (II): ##STR1## and pharmaceutically acceptable salts thereof the compounds of the formula (II) in which R.sup.1 is hydrogen are disclosed.
    Type: Grant
    Filed: September 1, 1988
    Date of Patent: December 5, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Kamlesh P. Vyas, Hanumath P. Kari
  • Patent number: 4808629
    Abstract: A new pharmaceutical composition for treating nonlymphatic leukemia, such as granulocytic and monocytic leukemia comprising Harringtonine, Homoharringtonine, Anethole, Oleanolic acid and Ginsenoside and method of making the same.
    Type: Grant
    Filed: May 14, 1987
    Date of Patent: February 28, 1989
    Inventor: Yaguang Liu
  • Patent number: 4767783
    Abstract: A gallstone dissolver comprises the following active ingredients (A) and (B);(A) a compound selected from the group consisting of fatty acid monoglycerides of C-6 to C-12, fatty acid diglycerides in liquid phase at 30.degree. C., fatty acid triglycerides in liquid phase at 30.degree. C., and fatty acids in liquid phase at 30.degree. C., and(B) a monoterpene.The coexistence of the fatty acid and monoterpene in the gallstone dissolver accelerates the sulubility and dissolving velocity of cholesterol gallstones.A nonionic surfactant such as a polyoxyethylene sorbitan fatty acid ester, glycerin fatty acid ester, etc. may also be added to the above dissolver to further improve the performance of the dissolver.
    Type: Grant
    Filed: August 13, 1986
    Date of Patent: August 30, 1988
    Assignee: Kao Corporation
    Inventors: Kenji Hara, Jhoshin Okada